FTRE
Fortrea Holdings Inc. Common Stock
SERVICES-MEDICAL LABORATORIES
Best Medical Labs Stocks 2026 →
Fortrea (FTRE) Stock: Buy, Sell, or Hold?
$20.06
-0.32 (-1.57%)
▼
5d:
-1.96%
30d:
-6.0%
90d:
+15.22%
QUANTITATIVE VERDICT
HOLD
MODERATE Confidence (58%)
Quality Score
55/100
Position
OVERSOLD
30-Day Fair Range
$20.43 – $23.42
Position: OVERSOLD
Forward P/E & Valuation
18.0x
FAIR
vs 16.0x historical avg
Wall Street Target
$23.63
+17.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$18.97 / $23.51
Trend: Strong Uptrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
📊 HOLD: FTRE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Get Alerted When FTRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$34.74
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$21.57
7.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: FTRE is currently trading at $20.06, which is considered oversold relative to its 30-day fair value range of $20.43 to $23.42. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.0) compared to its historical average (16.0). At these levels, the market is pricing in 4.0% annual earnings growth.
Technical Outlook: Technically, FTRE is in a strong uptrend. Immediate support is located at $18.97, while resistance sits at $23.51.
Market Sentiment: FTRE scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.62 (+17.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, FTRE is in a strong uptrend. Immediate support is located at $18.97, while resistance sits at $23.51.
Market Sentiment: FTRE scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $23.62 (+17.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$20.43 -
$23.42
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
Trading Range & Key Levels
30-Day Trading Range
$20.43 -
$23.42
Current vs Trading Range
OVERSOLD
Support Level
$18.97
Resistance Level
$23.51
Current Trend
Strong Uptrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($23.62)
- BULLISH: Expecting earnings turnaround to 4.0% growth with -1.4% revenue growth
Fundamental Context
Forward P/E (Next Year Est.)
17.99
Wall Street Target
$23.63
(+17.8%)
Revenue Growth (YoY)
-1.4%
Earnings Growth (YoY)
-57.4%
Profit Margin
-2.6%
Valuation Premium vs History
+4.0% premium
PE vs Historical
18.0 vs 16.0
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.0%
(market-implied from PE analysis)
1-Year Target
$20.86
(+4%)
2-Year Target
$21.70
(+8%)
3-Year Target
$22.56
(+13%)
3-Yr Target (if PE normalizes)
(PE: 18→16)
PE COMPRESSION
$20.07
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 30.0%)
$48.70
(+143%)
Base:
(SPY PE: 18.0, Growth: 30.0%)
$44.12
(+120%)
Bear:
(PE: 15.3, Growth: 30.0%)
$37.50
(+87%)
Share FTRE Analysis
Share this live FTRE analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (FTRE)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Oct 29, 2026
Daily AI digest
AI Retail Discussion Summary:
Fortrea Holdings (FTRE) reported Q3 earnings with a beat on EPS and raised full-year guidance for revenue and adjusted EBITDA. The company has completed major cost alignment actions and is now focusing on operational execution.
Key Retail Themes:
earnings beat
raised guidance
operational execution
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 7:59 PM ET
Data refreshes hourly during market hours. Next update: 8:59 PM
Data refreshes hourly during market hours. Next update: 8:59 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is FTRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$91 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$266 | 55 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 52 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 52 HOLD |
|
WVE
Wave Life Sciences Ltd |
STRONG BUY
21 analysts |
$17 | 37 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive FTRE Research Pages
